Market News & Trends
SGS Announces Amino Acid Analytical Services
SGS Life Science Services recently announced it is now able to offer a full range of analytical methods to identify amino acid impurities within pharmaceutical…
SteadyMed Raises $12.2 Million
SteadyMed Ltd. recently announced it has secured $12.2 million in an equity financing. The financing was co-led by funds advised by subsidiaries of Federated Investors…
West Launches High-Quality Flip-Off Plus Seals
West Pharmaceutical Services, Inc. (NYSE: WST) recently announced the availability of a new sterile drug vial seal, the Flip-Off® PlusRU seal. Part of West’s Flip-Off®…
Noxilizer Announces Board of Directors Addition
Noxilizer, Inc. recently announced Herbert C. Buchanan Jr., President, IU Health Methodist and University Hospitals, will join its Board of Directors. The company plans to…
Vaxxas Raises $20 Million to Accelerate Commercialization of Novel Vaccine Platform
Vaxxas recently announced it has secured equity funding of $20 million from new and existing investors. These funds represent the first closing of a Series…
BioSpectra Welcomes New Director, Offering Direct Access to the Highest Compliance Excipients & APIs
BioSpectra recently announced the appointment of Thomas Donnelly as Director of Sales and Marketing. Mr. Donnelly will manage direct sales and business activities for BioSpectra…
Affinivax Announces Collaboration to Advance Lead Vaccine Candidate
Affinivax Inc. recently announced it has entered into a collaboration agreement with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate…
FDA Approves Genentech’s Lucentis (Ranibizumab Injection)
Genentech, a member of the Roche Group, recently announced that the US FDA approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in…
Achillion Achieves 100% SVR12 In Phase II Trial
Achillion Pharmaceuticals, Inc. recently announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase II study to evaluate the efficacy, safety, and tolerability of 6…
Strategic Science & Technologies Initiates Phase I Study to Evaluate Topical Sildenafil
Strategic Science & Technologies recently announced the initiation of a Phase I trial of SST-6006, a first-in-class topical sildenafil product candidate in development for the…